Secondary interstitial lung disease specific to childhood associated with a metabolic disease

Secondary interstitial lung disease specific to childhood associated with a metabolic disease (Orphanet code 264719) is a classification category within the broader group of childhood interstitial lung diseases (chILD). This designation encompasses a heterogeneous group of pulmonary disorders in which interstitial lung disease develops as a secondary consequence of an underlying inborn error of metabolism. Metabolic diseases that can lead to this form of interstitial lung disease in children include lysosomal storage disorders (such as Gaucher disease, Niemann-Pick disease, and Hermansky-Pudlak syndrome), glycogen storage diseases, and other inherited metabolic conditions in which abnormal accumulation of substrates or metabolic byproducts damages the lung parenchyma. The lungs are the primary organ system affected, with pathological changes occurring in the pulmonary interstitium — the tissue and space surrounding the air sacs (alveoli). This leads to impaired gas exchange and progressive respiratory compromise. Key clinical features include chronic cough, progressive dyspnea (difficulty breathing), tachypnea (rapid breathing), hypoxemia (low blood oxygen levels), failure to thrive, and exercise intolerance. Chest imaging typically reveals diffuse interstitial infiltrates, ground-glass opacities, or other parenchymal abnormalities. The severity and progression depend heavily on the specific underlying metabolic disorder. Treatment is directed at managing both the underlying metabolic disease and the pulmonary complications. For certain storage disorders, enzyme replacement therapy or substrate reduction therapy may slow or partially reverse lung involvement. Supportive respiratory care, including supplemental oxygen, pulmonary rehabilitation, and nutritional support, forms a cornerstone of management. In severe cases, lung transplantation may be considered. Because this is a grouping category rather than a single disease entity, prognosis and treatment response vary widely depending on the specific metabolic diagnosis.

Common questions about Secondary interstitial lung disease specific to childhood associated with a metabolic disease